JCO Clinical Cancer Informatics

Koneksa Announces New Multi-Domain Model for Functional Status Assessment Enabled by Digital Health Technologies

Retrieved on: 
Thursday, January 4, 2024
Data Management, Other Science, Practice Management, Physical Therapy, FDA, Technology, Research, Other Health, Surgery, Pharmaceutical, Oncology, Medical Devices, Hospitals, Genetics, Clinical Trials, Biotechnology, Software, Health, Science, Hardware, Continuity, Montefiore Medical Center, Influencer marketing, Clinical and Translational Science, PLOS, Informatics, Clinical trial, Cancer, Observational study, Elective surgery, JCO Clinical Cancer Informatics, Patient, Data collection, Protein, Vital signs, Area studies, Algorithm, Research fellow, Medical imaging

The paper, titled: “A Proposed Multi-Domain Digital Model for Capturing Functional Status and Health-Related Quality of Life in Oncology,” highlights the importance of collecting continuous 24/7 functional status measures digitally to enable better clinical decisions and outcomes assessment.

Key Points: 
  • The paper, titled: “A Proposed Multi-Domain Digital Model for Capturing Functional Status and Health-Related Quality of Life in Oncology,” highlights the importance of collecting continuous 24/7 functional status measures digitally to enable better clinical decisions and outcomes assessment.
  • However, the assessment of patients' functional status – encompassing physical, cognitive, and behavioral functioning – holds increasing significance in influencing clinical decisions and understanding treatment outcomes.
  • Koneksa's innovative digital model aims to address limitations in existing functional status assessments by leveraging digital health technologies (DHTs) for both objective and self-reported outcomes.
  • ”
    Continuous real-time digital monitoring of functional status can assess the health and well-being of patients in other diseases, such as in orthopedics.

Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer Informatics

Retrieved on: 
Monday, June 26, 2023
Time trial, Therapy, CCI, ESR1, Clinical trial, Cancer, Fulvestrant, Mutation, JCO Clinical Cancer Informatics, Research, JCO, Trial of the century, Eli Lilly, Tempus, Patient, IRB, Oncology, TIME, Breast cancer, Pharmaceutical industry, Nursing

The second method used the Tempus TIME Trial Network that would rapidly open the trial, at the site of care, after identifying a patient with a mutation of interest and eligibility for the trial.

Key Points: 
  • The second method used the Tempus TIME Trial Network that would rapidly open the trial, at the site of care, after identifying a patient with a mutation of interest and eligibility for the trial.
  • Sermonix was able to leverage Tempus’ network of individual clinical sites that use a pre-approved clinical trial agreement and regulatory process, as well as a central IRB.
  • The duration for full clinical trial agreement execution averaged 200.5 days for traditional sites, compared to 7.6 days for TIME Trial sites.
  • These results demonstrate the value of employing both models for biomarker-driven studies.”
    Tempus is an industry leader analyzing multimodal data to identify actionable clinical trial options for cancer patients.

Florida Cancer Specialists & Research Institute Supports American Cancer Society Guidelines for Colonoscopies

Retrieved on: 
Tuesday, November 22, 2022
COVID-19, Life expectancy, Oslo University Hospital, American Society of Clinical Oncology, U.S. News & World Report, Colorectal cancer, University, Human, Colonoscopy, Colon, ACS, Diagnosis, University of Florida Cancer and Genetics Research Complex, ASCO, Polyp, Cell, The New England Journal of Medicine, Cancer, Geography, Rectum, Risk, Health, Physician, Patient, Mortality, American Cancer Society, Large intestine, Informatics, Community Oncology Alliance, COA, Society, JCO Clinical Cancer Informatics, FCS, Death, Avalere Health, Polyp (medicine), Water, News, Clinical trial, Woman, Immunotherapy, Drug development, Pharmaceutical industry, Medical imaging, Mobile phone, Health insurance, MD

Dr. Karen Knudsen, Chief Executive Officer at the American Cancer Society, shared in response to the study: Preventive cancer screenings are the best and most trusted way to save lives.

Key Points: 
  • Dr. Karen Knudsen, Chief Executive Officer at the American Cancer Society, shared in response to the study: Preventive cancer screenings are the best and most trusted way to save lives.
  • Thats why the American Cancer Society recommends colorectal cancer screening, including colonoscopy, for adults beginning at age 45.
  • About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
    Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida.
  • The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.

Florida Cancer Specialists & Research Institute Supports American Cancer Society Guidelines for Colonoscopies

Retrieved on: 
Tuesday, November 22, 2022
COVID-19, Life expectancy, Oslo University Hospital, American Society of Clinical Oncology, U.S. News & World Report, Colorectal cancer, University, Human, Colonoscopy, Colon, ACS, Diagnosis, University of Florida Cancer and Genetics Research Complex, ASCO, Polyp, Cell, The New England Journal of Medicine, Cancer, Geography, Rectum, Risk, Health, Physician, Patient, Mortality, American Cancer Society, Large intestine, Informatics, Community Oncology Alliance, COA, Society, JCO Clinical Cancer Informatics, FCS, Death, Avalere Health, Polyp (medicine), Water, News, Clinical trial, Woman, Immunotherapy, Drug development, Pharmaceutical industry, Medical imaging, Mobile phone, Health insurance, MD

Dr. Karen Knudsen, Chief Executive Officer at the American Cancer Society, shared in response to the study: Preventive cancer screenings are the best and most trusted way to save lives.

Key Points: 
  • Dr. Karen Knudsen, Chief Executive Officer at the American Cancer Society, shared in response to the study: Preventive cancer screenings are the best and most trusted way to save lives.
  • Thats why the American Cancer Society recommends colorectal cancer screening, including colonoscopy, for adults beginning at age 45.
  • About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
    Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida.
  • The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.

Roche introduces the navify brand for its digital health solutions at HLTH 2022

Retrieved on: 
Friday, November 4, 2022
Genentech, JCO Clinical Cancer Informatics, ROG, Pharma, Algorithm, Hospital, Internal medicine, Health, Time, Multimedia, Core, Dow Jones, World Health Organization, Medtech, SEPT2, Generate, Digital, Digital Solutions, Patient, Internet, Commercial National Security Algorithm Suite, Test, Physician, Health equity, Cervical cancer, SMART, Hoffmann-La Roche, RO, Technology, Informatics, Software, Laboratory, Archive, Solution, Fine chemical, Online shopping, Medical device, Pharmaceutical industry, Healthcare, Industry, Chugai Pharmaceutical Co., Diagnosis

Roche unifies its digital health portfolio under the navify brand, providing a range of next generation software solutions.

Key Points: 
  • Roche unifies its digital health portfolio under the navify brand, providing a range of next generation software solutions.
  • The navify digital solutions reinforce Roche's commitment to help providers and innovators connect with patients for better access, experience and delivery of care.
  • BASEL, Switzerland, Nov. 4, 2022 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today at the HLTH 2022 meeting in Las Vegas, NV, US, that its digital health portfolio will now be available under the navify brand.
  • navify Oncology portfolio, navify Diagnostic Optimization, navify Infection Management, navify Algorithm Suite, and navify Kidney Companion).

Roche introduces the navify brand for its digital health solutions at HLTH 2022

Retrieved on: 
Friday, November 4, 2022
Genentech, JCO Clinical Cancer Informatics, ROG, Pharma, Algorithm, Hospital, Internal medicine, Health, Time, Core, Dow Jones, World Health Organization, Medtech, SEPT2, Generate, Digital, Digital Solutions, Patient, Internet, Commercial National Security Algorithm Suite, Test, Physician, Health equity, Cervical cancer, SMART, Hoffmann-La Roche, RO, Technology, Informatics, Software, Laboratory, Archive, Solution, Fine chemical, Online shopping, Medical device, Pharmaceutical industry, Healthcare, Industry, Chugai Pharmaceutical Co., Diagnosis

Roche unifies its digital health portfolio under the navify brand, providing a range of next generation software solutions.

Key Points: 
  • Roche unifies its digital health portfolio under the navify brand, providing a range of next generation software solutions.
  • The navify digital solutions reinforce Roche's commitment to help providers and innovators connect with patients for better access, experience and delivery of care.
  • BASEL, Switzerland, Nov. 4, 2022 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today at the HLTH 2022 meeting in Las Vegas, NV, US, that its digital health portfolio will now be available under the navify brand.
  • navify Oncology portfolio, navify Diagnostic Optimization, navify Infection Management, navify Algorithm Suite, and navify Kidney Companion).

Breast and Prostate Cancer Diagnoses Still Lagging During Second Full Year of COVID-19 Pandemic, Quest Diagnostics Health Trends® Study Finds

Retrieved on: 
Tuesday, October 11, 2022
JCO, Physician, Lung, Quest Diagnostics, Allergy, Informatics, Soul food health trends, DGX, Risk, American Association for Cancer Research, Breast, JCO Clinical Cancer Informatics, Drug, NYSE, ASCO, Society, Patient, Degenerative disease, Hospital, Hepatitis, Asthma, Research, Multimedia, American Society of Clinical Oncology, Cancer, Institute of Cancer Research, Medical Affairs Bureau, Prostate, AACR, MD, American Association, Association, Breast cancer, View, Health, Diabetes, Prostate cancer, DTI, Population Health Management, Adult, Journal, Sexual abuse, Database, Travel, Lyme disease, COVID-19, American Journal of Clinical Oncology, Public health, Medical imaging, Pharmaceutical industry, Animal

SECAUCUS, N.J., Oct. 11, 2022 /PRNewswire/ -- More than two years after the COVID-19 pandemic began, diagnoses of breast and prostate cancer, two of the nation's leading causes of cancer death, continue to lag behind pre-pandemic levels, according to a nationally representative Quest Diagnostics Health Trends® study by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services.

Key Points: 
  • While cancer diagnoses increased over the subsequent two years, the gains have not been enough to offset diagnoses delayed or missed earlier in the pandemic.
  • Diagnoses of prostate and breast cancer remained significantly below pre-pandemic levels as late as period 3, at 17% and 11% respectively.
  • "As an oncologist, I am particularly disturbed by the finding that cancer diagnoses for breast and prostate cancer are well below pre-pandemic levels.
  • Breast and prostate cancer are expected to account for nearly 30% of new cancer diagnoses in 2022.

Aspira Women’s Health Reports Second Quarter 2022 Financial Results

Retrieved on: 
Wednesday, August 10, 2022
Woman, JCO Clinical Cancer Informatics, Hospital, Urology, Risk, Endometriosis, Informatics, GLOBE, Investment, Ovarian cancer, Chief executive officer, Eastern Time Zone, Research, Marketing, Patient, Â, Co-marketing, Partnership, Intention, Detection, Conference call, Operational excellence, MicroRNA, Protein, Physician, Second, Conference, Medical school, Pharmaceutical industry, Video game, Animal, Health insurance, Online gambling, Aspira, Innovation, Growth

AUSTIN, Texas, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2022.

Key Points: 
  • ET
    AUSTIN, Texas, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aspira Womens Health Inc. (Aspira) (Nasdaq: AWH), a bio-analytical based womens health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2022.
  • Highlights of Second Quarter 2022 vs. Second Quarter 2021
    Product revenue for the three months ended June 30, 2022 was $2.0 million compared to $1.7 million for the same period in 2021, an increase of 17%.
  • Highlights of Second Quarter 2022 vs. First Quarter 2022:
    Product revenue was $2.0 million for the three months ended June 30, 2022, compared to $1.8 million for the three months ended March 31, 2022, an increase of 10%.
  • Aspira utilized $6.4 million in the second quarter of 2022, compared to $10.3 million in the first quarter of 2022 and $6.4 million for the second quarter of 2021.

Aspira Women’s Health Announces Publication of Paper Validating OvaWatch™ Algorithm in the Detection of Ovarian Cancer

Retrieved on: 
Thursday, June 16, 2022
Axia, Publication, Risk assessment, Forward-looking statement, Protein, Health, Plasma, Legislation, GLOBE, Solution, Annual report, Innovation, Compliance, CEO, Aspira, Private Securities Litigation Reform Act, Physician, JCO Clinical Cancer Informatics, Hereditary breast–ovarian cancer syndrome, Paper, Genetic testing, Breast, FDA, COVID-19, Quest Diagnostics, Genetics, Endometriosis, Adoption, Algorithm, Detection, Biomarker, HIV disease progression rates, Informatics, Patient, Diagnosis, Woman, Risk, Laboratory, Mortality, LDT, Research, Prognosis, AbbVie, Awareness, Birth control, Ovarian cancer

AUSTIN, Texas, June 16, 2022 (GLOBE NEWSWIRE) -- Aspira Womens Health Inc. (Aspira), a bio-analytical based womens health company focused on gynecologic disease, today announced the online publication of a paper validating its OvaWatchalgorithm in the detection of ovarian cancer in the June issue of JCO Clinical Cancer Informatics.

Key Points: 
  • AUSTIN, Texas, June 16, 2022 (GLOBE NEWSWIRE) -- Aspira Womens Health Inc. (Aspira), a bio-analytical based womens health company focused on gynecologic disease, today announced the online publication of a paper validating its OvaWatchalgorithm in the detection of ovarian cancer in the June issue of JCO Clinical Cancer Informatics.
  • Early detection of ovarian cancer is key to helping to reduce mortality; however, other current noninvasive risk assessment measures on the market vary in their usefulness.
  • There is tremendous need for early ovarian cancer detection and stratification, especially for women presenting with adnexal masses.
  • About Aspira Womens Health Inc.
    Aspira Womens Health Inc. is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women.

APSHO Wins Association Award for National Oncology Leadership Summit

Retrieved on: 
Saturday, September 12, 2020
Academic journals, Health, JCO Clinical Cancer Informatics, Oncology nursing, JCO, Oncology

LAWRENCEVILLE, N.J., Sept. 12, 2020 /PRNewswire-PRWeb/ -- The Advanced Practitioner Society for Hematology and Oncology (APSHO) was awarded the 2020 Power of A (Association) Silver Award from the American Society of Association Executives (ASAE) for its work organizing a national oncology leadership summit for nurse practitioners, physician assistants, and pharmacists.

Key Points: 
  • LAWRENCEVILLE, N.J., Sept. 12, 2020 /PRNewswire-PRWeb/ -- The Advanced Practitioner Society for Hematology and Oncology (APSHO) was awarded the 2020 Power of A (Association) Silver Award from the American Society of Association Executives (ASAE) for its work organizing a national oncology leadership summit for nurse practitioners, physician assistants, and pharmacists.
  • "This award celebrates APSHO's extraordinary work in uplifting advanced practice leaders in oncology," said Executive Director of APSHO, Wendy H. Vogel, MSN, FNP, AOCNP.
  • APSHO took Silver in the 2020 award category of The Power of Industry/Professional Advancement for the National Oncology Advanced Practitioner Leadership Summit, which took place at JADPRO Live 2019 and aimed to address critical oncology issues by bringing oncology advanced practice leaders together to collaborate on leadership challenges.
  • Harborside also manages the advertising sales for ASCO's suite of publications, including JCO Oncology Practice, JCO Global Oncology, JCO Clinical Cancer Informatics, and JCO Precision Oncology.